World Scientific
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.
No Access

Chapter 3: An Introduction to New Oral Anticoagulants

    https://doi.org/10.1142/9781786344946_0003Cited by:0 (Source: Crossref)
    Previous
    Next
    Abstract:

    The following sections are included:

    • New oral anticoagulants (NOACs) are growing in popularity as an alternative to warfarin.

    • No monitoring of coagulation is required.

    • Fixed once or twice daily dosing.

    • Bridging with low molecular weight heparin (LMWH) is not required when commencing treatment with NOACs due to their quick onset of action.

    • Dose adjustments are required in renal failure.

    • NOACs have a favourable safety profile in comparison to warfarin, but care is required for the elderly who may be at risk of a gastrointestinal bleed.

    • NOACs can be used in VTE prevention for elective orthopaedic surgery, VTE treatment and prevention of arterial thromboembolism in patients with atrial fibrillation.

    • NOACs are not yet recommended for anticoagulation control in patients with prosthetic heart valve and acute coronary syndrome.

    back